• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.

作者信息

Toyoda Hidenori, Kumada Takashi, Tada Toshifumi

机构信息

Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.

出版信息

Hepatology. 2016 Nov;64(5):1818-1819. doi: 10.1002/hep.28632. Epub 2016 Jun 7.

DOI:10.1002/hep.28632
PMID:27136189
Abstract
摘要

相似文献

1
Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.在丙型肝炎病毒（HCV）无干扰素治疗时代，患者背景的变化可能会增加持续病毒学应答（SVR）后肝细胞癌（HCC）的发生率。
Hepatology. 2016 Nov;64(5):1818-1819. doi: 10.1002/hep.28632. Epub 2016 Jun 7.
2
Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.在日本，接受无干扰素治疗与基于干扰素治疗并实现持续病毒学应答的慢性丙型肝炎患者的背景特征差异，以及丙型肝炎病毒根除后发生肝细胞癌的风险。
J Viral Hepat. 2017 Jun;24(6):472-476. doi: 10.1111/jvh.12665. Epub 2017 Jan 11.
3
Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.基于干扰素的疗法实现的持续丙型肝炎病毒清除可降低乙肝和丙肝双重感染患者的肝细胞癌发生率。
Antivir Ther. 2011;16(7):959-68. doi: 10.3851/IMP1842.
4
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.根治性切除或消融术后的肝细胞癌复发：HCV 清除的影响不依赖于干扰素的使用。
Aliment Pharmacol Ther. 2017 Jan;45(1):160-168. doi: 10.1111/apt.13821. Epub 2016 Oct 28.
5
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.根治性治疗肝细胞癌后无干扰素直接作用抗病毒治疗丙型肝炎是否会导致 HCC 意外复发？日本红十字会医院肝脏研究组的一项多中心研究。
PLoS One. 2018 Apr 16;13(4):e0194704. doi: 10.1371/journal.pone.0194704. eCollection 2018.
6
Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.在接受包括干扰素在内的抗病毒治疗后获得持续病毒学应答的慢性丙型肝炎患者，在接受肝细胞癌肝切除术前的良好预后。
Anticancer Res. 2015 Dec;35(12):6963-9.
7
Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.慢性丙型肝炎病毒感染获得持续病毒学应答的非肝硬化患者发生肝细胞癌的危险因素。
J Gastroenterol Hepatol. 2015 Jul;30(7):1183-9. doi: 10.1111/jgh.12915.
8
Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.加拿大丙型肝炎患者持续病毒学应答对肝细胞癌的长期影响。
J Hepatol. 2017 Mar;66(3):504-513. doi: 10.1016/j.jhep.2016.10.028. Epub 2016 Nov 4.
9
Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor.丙型肝炎病毒相关肝细胞癌根治性治疗后实现的持续病毒学应答作为一个独立的预后因素。
J Gastroenterol Hepatol. 2015 Jul;30(7):1197-204. doi: 10.1111/jgh.12925.
10
Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.组织病理学改善停滞是丙型肝炎病毒清除后肝细胞癌发展的预测因子。
PLoS One. 2018 Mar 13;13(3):e0194163. doi: 10.1371/journal.pone.0194163. eCollection 2018.

引用本文的文献

1
Lycorine inhibits migration and proliferation of hepatocellular carcinoma cells by reducing transketonase expression.石蒜碱通过降低转酮醇酶的表达来抑制肝癌细胞的迁移和增殖。
J Cancer. 2024 Feb 4;15(7):1826-1836. doi: 10.7150/jca.93026. eCollection 2024.
2
Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy.接受直接抗病毒治疗后获得持续病毒学应答的慢性丙型肝炎患者肝细胞癌的发生情况。
Hepatol Forum. 2022 Sep 23;3(3):82-87. doi: 10.14744/hf.2022.2022.0016. eCollection 2022 Sep.
3
Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs.
用于丙型肝炎病毒感染和肝细胞癌的直接抗病毒药物：事实与谬误。
Transl Cancer Res. 2019 Apr;8(Suppl 3):S223-S232. doi: 10.21037/tcr.2019.04.01.
4
High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma.SLC41A3的高表达与肝细胞癌的不良预后相关。
Onco Targets Ther. 2021 May 5;14:2975-2988. doi: 10.2147/OTT.S296187. eCollection 2021.
5
Impact of COVID-19 pandemic on surveillance of hepatocellular carcinoma: A study in patients with chronic hepatitis C after sustained virologic response.新型冠状病毒肺炎大流行对肝细胞癌监测的影响：一项针对持续病毒学应答后慢性丙型肝炎患者的研究
GastroHep. 2020 Sep;2(5):247-252. doi: 10.1002/ygh2.418. Epub 2020 Sep 3.
6
High expression of FOXO3 is associated with poor prognosis in patients with hepatocellular carcinoma.FOXO3高表达与肝细胞癌患者的不良预后相关。
Oncol Lett. 2020 Apr;19(4):3181-3188. doi: 10.3892/ol.2020.11430. Epub 2020 Mar 3.
7
Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma.在肝细胞癌早期复发的三级预防中，干扰素优于直接抗病毒治疗。
Cancers (Basel). 2019 Dec 19;12(1):23. doi: 10.3390/cancers12010023.
8
Is direct acting antiviral therapy for hepatitis c viral infection associated with increased risk of hepatocellular carcinoma before or after liver transplantation?丙型肝炎病毒感染的直接抗病毒治疗与肝移植前后肝细胞癌风险增加有关吗？
Hepatobiliary Surg Nutr. 2019 Oct;8(5):563-565. doi: 10.21037/hbsn.2019.05.10.
9
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?直接作用抗病毒治疗的肝移植患者肝细胞癌复发风险是否增加？
Hepatol Int. 2019 Mar;13(2):190-198. doi: 10.1007/s12072-019-09930-x. Epub 2019 Jan 24.
10
hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents.接受直接抗病毒药物治疗的丙型肝炎肝硬化患者肝细胞癌的发生情况
Hepat Oncol. 2018 Jul 25;5(1):HEP06. doi: 10.2217/hep-2018-0003. eCollection 2018 Jan.